OncoMatch/Clinical Trials/NCT05200650
A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor
Is NCT05200650 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TumoCure for head and neck cancer.
Treatment: TumoCure — IntraGel's polymer-based Cisplatin loaded Gel (TumoCure) is a single injectable compound, aimed at localized chemotherapy treatment. The treatment is offered to patients who currently have no other available treatment options, either due to inefficacy, intolerability or inapplicability of standard treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic chemotherapy
Subject who was treated with systemic chemotherapy during the 4 weeks preceding screening.
Lab requirements
Blood counts
blood leukocytes count <1.5 *103/microl or platelets <75 *103/microl [excluded]
Kidney function
s-creatinine ≥ 1.5xuln or creatinine clearance < 40 ml/min [excluded]
Liver function
asat, alat, bilirubin > 1.5xuln and pk-inr > 1.5, or a known medical history of liver cirrhosis or portal hypertension [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05200650 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages